<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377792</url>
  </required_header>
  <id_info>
    <org_study_id>SSH-FQ1</org_study_id>
    <nct_id>NCT01377792</nct_id>
  </id_info>
  <brief_title>Study of Long-term Treatment With Hypertonic Saline in Patients With Cystic Fibrosis</brief_title>
  <official_title>Phase 4 Study of the Efficacy of Long-term Treatment With Hypertonic Saline on Pulmonary Exacerbations in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adelaida Lamas Ferreiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Ramon y Cajal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase IV clinical trial, multicentric (3 Hospitals in Madrid) controlled, prospective, open
      and randomized of long-term treatment with hypertonic saline in cystic fibrosis patients. The
      purpose of this study is to verify if the long term inhalation (48 weeks) of major volume (10
      ml) increases the free time without pulmonary exacerbation, and if this increase is superior
      to the obtained with the inhalation of the standard volume (5 ml) that has been advocated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Free time, specified in days, of pulmonary exacerbation</measure>
    <time_frame>12 months</time_frame>
    <description>Exact number of days, along 48 weeks of tretment with hypertonic saline, in wich the patient is free of pulmonary excaerbation symptoms and does not need antibiotics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in lung function test measured by spirometry</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers during the treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of inflammatory markers in induced sputum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement of quality of life of patients during treatment by CFQ-R test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>5 ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10 ml</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypertonic saline</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>5 ml</arm_group_label>
    <arm_group_label>10 ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Cystic fibrosis

          -  Over 6 years old

          -  FEV1 over than 30%

          -  Must be able to perform a spirometry

          -  Must be able to perform induced sputum

          -  Must tolerate the maximum dose of 10 ml hypertonic saline

          -  No oral neither intravenous treatment within the previous 2 weeks before the beginning
             of the study

          -  No treatment with hypertonic saline in the 2 weeks before

        Exclusion Criteria:

          -  No clinical diagnosis of Cystic Fibrosis

          -  No tolerance of 10 ml of hypertonic saline

          -  Positive pregnancy test

          -  No tolerance of Beta2-agonist

          -  Treatment with corticosteroids

          -  FEV1 &lt; 30%

          -  Liver and/or lung transplantation

          -  Oxygen treatment

          -  Hospital admission within the 4 previous weeks

          -  Oral or intravenous antibiotic treatment within the 2 previous weeks

          -  Smokers

          -  Pulmonary colonisation with Burkholderia cepacia complex
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adelaida Lamas, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Cystic Fibrosis Unit. Ram√≥n y Cajal University Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Ramon y Cajal</investigator_affiliation>
    <investigator_full_name>Adelaida Lamas Ferreiro</investigator_full_name>
    <investigator_title>Dra.Adelaida Lamas Ferreiro</investigator_title>
  </responsible_party>
  <keyword>hypertonic saline</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>pulmonary inflammation</keyword>
  <keyword>pulmonary exacerbation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

